These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34890538)

  • 1. Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.
    Croda J; Ranzani OT
    Lancet Infect Dis; 2022 Apr; 22(4):430-432. PubMed ID: 34890538
    [No Abstract]   [Full Text] [Related]  

  • 2. mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
    Larkin HD
    JAMA; 2022 Jun; 327(23):2280. PubMed ID: 35727270
    [No Abstract]   [Full Text] [Related]  

  • 3. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
    Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
    J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine.
    Tichmann-Schumann I; Soemantri P; Behre U; Disselhoff J; Mahler H; Maechler G; Sänger R; Jacquet JM; Schuerman L
    Pediatr Infect Dis J; 2005 Jan; 24(1):70-7. PubMed ID: 15665713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
    Rennels MB; Englund JA; Bernstein DI; Losonsky GA; Anderson EL; Pichichero ME; Munoz FM; Wolff MC
    Pediatr Infect Dis J; 2000 May; 19(5):417-23. PubMed ID: 10819337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
    Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine.
    Larkin HD
    JAMA; 2022 Jul; 328(3):234. PubMed ID: 35852521
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.
    Zepp F; Behre U; Kindler K; Laakmann KH; Pankow-Culot H; Mannhardt-Laakmann W; Beckers F; Descamps D; Willems P
    Eur J Pediatr; 2007 Aug; 166(8):857-64. PubMed ID: 17541639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.
    Liao Y; Zhang Y; Zhao H; Pu J; Zhao Z; Li D; Fan S; Yu L; Xu X; Wang L; Jiang G; Liu L; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):1112-1115. PubMed ID: 34057040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
    Martinón-Torres F; Diez-Domingo J; Feroldi E; Jordanov E; B'Chir S; Da Costa X
    Pediatr Infect Dis J; 2019 Mar; 38(3):317-322. PubMed ID: 30408001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.
    Cao Y; Hao X; Wang X; Wu Q; Song R; Zhao D; Song W; Wang Y; Yisimayi A; Wang W; Zhang W; Du J; Yu H; Xie XS; Jin R
    Cell Res; 2022 Jan; 32(1):107-109. PubMed ID: 34862467
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.
    Rouers EDM; Bruijning-Verhagen PCJ; van Gageldonk PGM; van Dongen JAP; Sanders EAM; Berbers GAM
    JAMA; 2020 Sep; 324(11):1068-1077. PubMed ID: 32930758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine.
    Madhi SA; Cutland C; Jones S; Groome M; Ortiz E
    S Afr Med J; 2011 Nov; 101(12):879-83. PubMed ID: 22273029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines.
    Bermal N; Szenborn L; Edison A; Hernandez M; Pejcz J; Majda-Stanislawska E; Gatchalian S; Fanic A; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2011 Jan; 30(1):69-72. PubMed ID: 20980933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.